{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:09:26Z","timestamp":1760238566287,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Slovenian Research Agency Programmes P3-0308 and P3-0154","award":["No. 20210061"],"award-info":[{"award-number":["No. 20210061"]}]},{"name":"the tertiary research and development project of the UMC Ljubljana","award":["No. 20210061"],"award-info":[{"award-number":["No. 20210061"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>To prevent atherothrombotic events, patients with peripheral arterial disease are typically prescribed antiplatelet therapy (APT). However, some of them receive anticoagulant therapy (ACT) due to comorbidities. Our aim was to determine possible differences in the effectiveness and safety of both treatments in patients after endovascular femoropopliteal revascularisation. We retrospectively analysed 1247 patients after successful femoropopliteal revascularisation performed in a single tertiary medical centre and classified them into the ACT or APT group, based on their prescribed treatment. The groups were characterised by descriptive statistics, and their characteristics were adjusted for confounders by propensity score matching. Effectiveness and safety outcomes were assessed within one year after revascularisation. The odds ratio for the composite outcome of all-cause death, PAD exacerbation, and major amputation due to vascular causes with ACT versus APT was 1.21 (95% CI 0.53\u20132.21; p = 0.484). The odds ratio for major bleeding as defined by the International Society on Thrombosis and Haemostasis with ACT versus APT was 0.77 (95% CI 0.13\u20133.84; p = 0.251). We found no statistically significant difference in the effectiveness and safety of ACT, when compared to APT in patients with similar cardiovascular risk factors and other baseline characteristics. Further prospective research is warranted.<\/jats:p>","DOI":"10.3390\/jcdd9070207","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:21:50Z","timestamp":1656634910000},"page":"207","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes after Endovascular Revascularisation of the Femoropopliteal Arterial Segment in Patients with Anticoagulant versus Antiplatelet Therapy: A Single-Centre Retrospective Cohort Study"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2110-4581","authenticated-orcid":false,"given":"Kevin","family":"Pelicon","sequence":"first","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-2501","authenticated-orcid":false,"given":"Klemen","family":"Petek","sequence":"additional","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-4344","authenticated-orcid":false,"given":"Anja","family":"Boc","sequence":"additional","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Institute of Anatomy, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2171-7794","authenticated-orcid":false,"given":"Vinko","family":"Boc","sequence":"additional","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-9863","authenticated-orcid":false,"given":"Nata\u0161a","family":"Kej\u017ear","sequence":"additional","affiliation":[{"name":"Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tja\u0161a","family":"Vi\u017eintin Cuderman","sequence":"additional","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7538-1595","authenticated-orcid":false,"given":"Ale\u0161","family":"Blinc","sequence":"additional","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"ESVM Guideline on Peripheral Arterial Disease","volume":"48","author":"Frank","year":"2019","journal-title":"Vasa"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J. Vasc. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM199202063260605","article-title":"Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease","volume":"326","author":"Criqui","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1570161117666190206230516","article-title":"Antithrombotic Therapy in Lower Extremity Artery Disease","volume":"18","author":"Aboyans","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without Aspirin in Patients with Stable Peripheral or Carotid Artery Disease: An International, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.11.050","article-title":"Long-Term Outcomes and Associations with Major Adverse Limb Events after Peripheral Artery Revascularization","volume":"75","author":"Hess","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2021.05.003","article-title":"Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial","volume":"78","author":"Bauersachs","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable Clinical Effectiveness with Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial","volume":"133","author":"Dake","year":"2016","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0272989X9401400109","article-title":"Patency Results of Percutaneous and Surgical Revascularization for Femoropopliteal Arterial Disease","volume":"14","author":"Hunink","year":"1994","journal-title":"Med. Decis. Making."},{"doi-asserted-by":"crossref","unstructured":"Pelicon, K., Petek, K., Boc, A., Boc, V., Kej\u017ear, N., Vi\u017eintin Cuderman, T., and Blinc, A. (2022). Effectiveness and Safety of Anticoagulant versus Antiplatelet Therapy in Patients after Endovascular Revascularisation of the Lower Limb. Zdrav. Vestn., advance online publication.","key":"ref_10","DOI":"10.6016\/ZdravVestn.3339"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: The European Stroke Organization (ESO)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_12","first-page":"499","article-title":"Die chirurgische Behandlung der peripheren Durchblutungsst\u00f6rungen","volume":"21","author":"Fontaine","year":"1954","journal-title":"Helv. Chir. Acta."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","article-title":"Recommended Standards for Reports Dealing with Lower Extremity Ischemia: Revised Version","volume":"26","author":"Rutherford","year":"1997","journal-title":"J. Vasc. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of Major Bleeding in Clinical Investigations of Antihemostatic Medicinal Products in Surgical Patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/aje\/kwq472","article-title":"Implementation of G-Computation on a Simulated Data Set: Demonstration of a Causal Inference Technique","volume":"173","author":"Snowden","year":"2011","journal-title":"Am. J. Epidemiol."},{"unstructured":"R Core Team (2019). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org.","key":"ref_16"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: Nonparametric Preprocessing for Parametric Causal Inference","volume":"42","author":"Ho","year":"2011","journal-title":"J. Stat. Softw."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1583\/13-4242.1","article-title":"Clinical Outcomes of 5358 Patients Undergoing Direct Open Bypass or Endovascular Treatment for Aortoiliac Occlusive Disease: A Systematic Review and Meta-Analysis","volume":"20","author":"Indes","year":"2013","journal-title":"J. Endovasc. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/CIRCULATIONAHA.107.689141","article-title":"Nitinol Stent Implantation versus Percutaneous Transluminal Angioplasty in Superficial Femoral Artery Lesions up to 10 Cm in Length: The Femoral Artery Stenting Trial (FAST)","volume":"116","author":"Krankenberg","year":"2007","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_21","first-page":"60","article-title":"Editor\u2019s Choice\u2014Risk of Major Amputation Following Application of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"63","author":"Katsanos","year":"2022","journal-title":"J. Vas. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1161\/CIRCULATIONAHA.117.024469","article-title":"A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease with a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative","volume":"135","author":"Hess","year":"2017","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jacc.2018.07.046","article-title":"Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial","volume":"72","author":"Baumgartner","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/152660280200900111","article-title":"Balloon Angioplasty and Stent Implantation Induce a Vascular Inflammatory Reaction","volume":"9","author":"Schillinger","year":"2002","journal-title":"J. Endovasc. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jcmm.13936","article-title":"The Effects of Stenting on Coronary Endothelium from a Molecular Biological View: Time for Improvement?","volume":"23","author":"Cornelissen","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in Peripheral Artery Disease after Revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N. Engl. J. Med."},{"doi-asserted-by":"crossref","unstructured":"Antonucci, E., Poli, D., Tosetto, A., Pengo, V., Tripodi, A., Magrini, N., Marongiu, F., and Palareti, G. (2015). The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS ONE, 10.","key":"ref_27","DOI":"10.1371\/journal.pone.0124719"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of Diagnosed Atrial Fibrillation in Adults National Implications for Rhythm Management and Stroke Prevention: The AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/clc.22813","article-title":"Atrial Fibrillation and Risk of Cardiovascular Events and Mortality in Patients with Symptomatic Peripheral Artery Disease: A Meta-Analysis of Prospective Studies","volume":"40","year":"2017","journal-title":"Clin. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.semvascsurg.2007.02.006","article-title":"Pharmacotherapy Before and After Revascularization: Anticoagulation, Antiplatelet Agents, and Statins","volume":"20","author":"Dagher","year":"2007","journal-title":"Semin. Vasc. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1526602818760488","article-title":"Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the EPAD Trial","volume":"25","author":"Moll","year":"2018","journal-title":"J. Endovasc. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The Impact of Bleeding Complications in Patients Receiving Target-Specific Oral Anticoagulants: A Systematic Review and Meta-Analysis","volume":"124","author":"Crowther","year":"2014","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-Specific Risks, Severity, Time Course, and Outcome of Bleeding on Long-Term Antiplatelet Treatment after Vascular Events: A Population-Based Cohort Study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/ehjcvp\/pvw011","article-title":"Efficacy and Safety of Prolonged Dual Antiplatelet Therapy: A Meta-Analysis of 15 Randomized Trials Enrolling 85 265 Patients","volume":"2","author":"Savarese","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1023\/B:EJEP.0000036568.02655.f8","article-title":"Loss to Follow-Up in Cohort Studies: How Much Is Too Much?","volume":"19","author":"Kristman","year":"2003","journal-title":"Eur. J. Epidemiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-018-1019-3","article-title":"Health-Related Quality of Life Impact of Minor and Major Bleeding Events during Dual Antiplatelet Therapy: A Systematic Literature Review and Patient Preference Elicitation Study","volume":"16","author":"Doble","year":"2018","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1007\/s00330-021-07692-5","article-title":"CT Perfusion in Peripheral Arterial Disease\u2014Hemodynamic Differences before and after Revascularisation","volume":"31","author":"Huellner","year":"2021","journal-title":"Eur. Radiol."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/9\/7\/207\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:41:15Z","timestamp":1760139675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/9\/7\/207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jcdd9070207"],"URL":"https:\/\/doi.org\/10.3390\/jcdd9070207","relation":{},"ISSN":["2308-3425"],"issn-type":[{"type":"electronic","value":"2308-3425"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}